Gliead Releases the Results of Phase 3 ASCENT-04/KEYNOTE-D19 Trials Shows Positive Effect for Combinational Use of Trodelvy® Plus Keytruda®
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the [Read More…]